Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
1057493,"Eli Lilly and Company",IN,100000000088,4561.05,07/24/2015,"Cash or cash equivalent",263815028,TRULICITY,"","THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION","","The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
1057493,"Eli Lilly and Company",IN,100000000088,353.30,04/06/2015,"In-kind items and services",263815030,TRULICITY,"","THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION","","The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."
